For example, it was found that intratumoral infusion of MSCs modified to overexpress IL-12 (MSC-IL-12) could result in the more prominent tumor-specific T-cell responses and antitumor impacts, and also more continued expressions of IL-12 and IFN-γ in both sera and tumor tissues than the injection of IL-12-expressing adenovirus (rAd/IL-12) in tumor-bearing xenografts (24). This evidence concerns the gene IFNG and neoplasm.